SODIUM PHOSPHATES- sodium phosphate, monobasic, monohydrate injection, solution

البلد: الولايات المتحدة

اللغة: الإنجليزية

المصدر: NLM (National Library of Medicine)

العنصر النشط:

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR), SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F) (PHOSPHATE ION - UNII:NK08V8K8HR)

متاح من:

Fresenius Kabi USA, LLC

INN (الاسم الدولي):

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

تركيب:

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 276 mg in 1 mL

طريقة التعاطي:

INTRAVENOUS

نوع الوصفة الطبية :

PRESCRIPTION DRUG

الخصائص العلاجية:

Sodium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake.  It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. Sodium phosphate is contraindicated in diseases where high phosphate or low calcium levels may be encountered, and in patients with hypernatremia.

ملخص المنتج:

These vials are flip-top, Single Dose Vials, packaged 25 vials per tray.  The vials marked with ‘‘PX’’ are partially filled to facilitate transfer of the contents. Do not administer unless solution is clear and seal intact.  Discard unused portion. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

الوضع إذن:

unapproved drug other

خصائص المنتج

SODIUM PHOSPHATES - SODIUM PHOSPHATE, MONOBASIC,
MONOHYDRATE INJECTION, SOLUTION
FRESENIUS KABI USA, LLC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this_
_labeling has not been approved by FDA. For further information about
unapproved_
_drugs, click here._
----------
SODIUM PHOSPHATES INJECTION USP
_3 mmol P and 4 mEq Na_ / _mL_
_FOR ADDITIVE USE ONLY AFTER DILUTION IN IV FLUIDS_
DESCRIPTION
Sodium Phosphates Injection, USP, 3 mmol/mL (millimoles/mL), is a
sterile,
nonpyrogenic, _concentrated solution _containing a mixture of
monobasic sodium
phosphate and dibasic sodium phosphate in Water for Injection.
The solution is administered after dilution by the intravenous route
as an electrolyte
replenisher. _It must not be administered undiluted._
Each mL contains: Monobasic sodium phosphate, monohydrate, 276 mg;
dibasic sodium
phosphate, anhydrous, 142 mg (equivalent to dibasic sodium phosphate,
heptahydrate,
268 mg); Water for Injection q.s. In the 5 mL and 15 mL product,
phosphoric acid
and/or NaOH may have been added for pH adjustment.
Each mL provides 3 mmol of phosphorus and 4 mEq sodium. It contains no
bacteriostat, antimicrobial agent or added buffer. The pH is 5.7
(approx.). The osmolar
concentration is 7 mOsmol/mL (calc.)
The solution is intended as an alternative to potassium phosphate to
provide phosphate
ion (PO
) for addition to large volume infusion fluids for intravenous use.
Sodium Phosphates, USP, monohydrate monobasic is chemically designated
NaH
PO
• H
O. Occurs as white, odorless crystals or granules freely soluble in
water.
Dibasic Sodium Phosphate, USP, anhydrous, is chemically designated Na
HPO
.
Occurs as a colorless or white granular salt freely soluble in water.
CLINICAL PHARMACOLOGY
Phosphorus in the form of organic and inorganic phosphate has a
variety of important
biochemical functions in the body and is involved in many significant
metabolic and
enzyme reactions in almost all organs and tissues. It exerts a
modifying influence on
the steady state of